Feb. 10, 2025 -- The FDA has approved a new antibiotic combination called Emblaveo to treat serious infections of the abdomen in adults who have few or no other treatment options. It will be ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, monobactam/beta-lactamase inhibitor combination antibiotic.

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

Please provide your email address to receive an email when new articles are posted on . Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this ...

(RTTNews) - AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first fixed-dose, intravenous monobactam/ Beta -lactamase ...